Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2018
At a glance
- Drugs BV NSCLC 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Bioven
- 10 Jun 2017 Biomarkers information updated
- 02 Feb 2017 This trial has been suspended in Germany as per European Clinical Trials Database record.
- 26 Jan 2017 Planned End Date changed from 1 Feb 2020 to 1 Mar 2020.